Biopharma Boardroom

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines...

September 20, 2023 | Wednesday | News

CPHI Annual Report predicts AI to transform all processes in drug development by 2026

The first part of the influential CPHI Annual Report predicts sizeable progress ahead for AI’s use in pharma, as despite the wider excitement around ...

September 14, 2023 | Thursday | Analysis

HUTCHMED Completes Patient Enrollment for Tazemetostat Study in Chinese Follicular Lymphoma

The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...

September 12, 2023 | Tuesday | News

Twist Bioscience Releases 2023 ESG Report and Quantifies Carbon Footprint of Manufacturing a Single Gene

“We took a big step forward in our ongoing commitment to deliver sustainable solutions to our customers, quantifying the impact of our proprietary ap...

August 23, 2023 | Wednesday | Reports

Study Explores Masimo PVi® for Targeted Liquid Therapy in Elderly Surgical Patients

Researchers found that fluid therapy guided by non-invasive and continuous PVi can reduce cardiopulmonary complications and infusion. Masimo (NASD...

August 22, 2023 | Tuesday | News

Bayer President, Sebastian Guth, Highlights Alarming Link: Rising Fear, Lack of Education, and Distrust Hinder Access to Vital Preventative Care

One in Four American Adults Would Rather Not Know They Have Cancer A new study from The Harris Poll, commissioned by Bayer, suggests fear factors ...

August 22, 2023 | Tuesday | Analysis

23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...